128 related articles for article (PubMed ID: 32286703)
1. Diagnostic significance of DNA methylation of PTEN and DAPK in thyroid tumors.
Wei F; Wu Y; Wang Z; Li Y; Wang J; Shao G; Yang Y; Shi B
Clin Endocrinol (Oxf); 2020 Aug; 93(2):187-195. PubMed ID: 32286703
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF
Khatami F; Larijani B; Heshmat R; Nasiri S; Haddadi-Aghdam M; Teimoori-Toolabi L; Tavangar SM
J Cell Physiol; 2020 Oct; 235(10):6954-6968. PubMed ID: 32017063
[TBL] [Abstract][Full Text] [Related]
3. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
4. Methylation markers differentiate thyroid cancer from benign nodules.
Stephen JK; Chen KM; Merritt J; Chitale D; Divine G; Worsham MJ
J Endocrinol Invest; 2018 Feb; 41(2):163-170. PubMed ID: 28612287
[TBL] [Abstract][Full Text] [Related]
5.
Li J; Yin Y; Huang H; Li M; Li H; Zhang M; Jiang C; Yang R
Epigenomics; 2023 Dec; 15(23):1257-1272. PubMed ID: 38126720
[No Abstract] [Full Text] [Related]
6. DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions.
Barros-Filho MC; Dos Reis MB; Beltrami CM; de Mello JBH; Marchi FA; Kuasne H; Drigo SA; de Andrade VP; Saieg MA; Pinto CAL; Kowalski LP; Rogatto SR
Thyroid; 2019 Sep; 29(9):1244-1254. PubMed ID: 31328658
[No Abstract] [Full Text] [Related]
7. Cell-free DNA methylation biomarker for the diagnosis of papillary thyroid carcinoma.
Hong S; Lin B; Xu M; Zhang Q; Huo Z; Su M; Ma C; Liang J; Yu S; He Q; Su Z; Li Y; Liu R; Guo Z; Lv W; Xiao H
EBioMedicine; 2023 Apr; 90():104497. PubMed ID: 36868052
[TBL] [Abstract][Full Text] [Related]
8. Analysis of BRAF(V600E) mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies.
Zhang B; Liu S; Zhang Z; Wei J; Qu Y; Wu K; Yang Q; Hou P; Shi B
Diagn Pathol; 2014 Mar; 9():45. PubMed ID: 24588959
[TBL] [Abstract][Full Text] [Related]
9. DNA Methylation Status of HYAL1 in Malignant and Benign Thyroid Nodules.
Li M; Yin Y; Zhang M; Jiang C; Li H; Yang R
Horm Metab Res; 2023 Dec; 55(12):869-875. PubMed ID: 38040022
[TBL] [Abstract][Full Text] [Related]
10. Expression and significance of IGF-1 and IGF-1R in thyroid nodules.
Liu YJ; Qiang W; Shi J; Lv SQ; Ji MJ; Shi BY
Endocrine; 2013 Aug; 44(1):158-64. PubMed ID: 23288662
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation analysis for the diagnosis of thyroid nodules - a pilot study with reference to BRAF(V) (600E) mutation and cytopathology results.
Chang H; Shin BK; Kim A; Kim HK; Kim BH
Cytopathology; 2016 Apr; 27(2):122-30. PubMed ID: 25988212
[TBL] [Abstract][Full Text] [Related]
12. New evidence on tumor suppressor activity of PTEN and KLLN in papillary thyroid carcinoma.
Razavi SA; Salehipour P; Gholami H; Sheikholeslami S; Zarif-Yeganeh M; Yaghmaei P; Modarressi MH; Hedayati M
Pathol Res Pract; 2021 Sep; 225():153586. PubMed ID: 34425332
[TBL] [Abstract][Full Text] [Related]
13. Expression level of NEAT1 differentiates benign and malignant thyroid nodules by regulating NEAT1/miR‑9/PTEN and NEAT1/miR‑124/PDCD6 signalling.
Zhao L; Zhou N; Zhao P
Int J Mol Med; 2020 Nov; 46(5):1661-1670. PubMed ID: 32901835
[TBL] [Abstract][Full Text] [Related]
14. Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer.
Hu S; Ewertz M; Tufano RP; Brait M; Carvalho AL; Liu D; Tufaro AP; Basaria S; Cooper DS; Sidransky D; Ladenson PW; Xing M
J Clin Endocrinol Metab; 2006 Jan; 91(1):98-104. PubMed ID: 16263813
[TBL] [Abstract][Full Text] [Related]
15. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
[TBL] [Abstract][Full Text] [Related]
16. A diagnostic model based on DNA methylation haplotype block characteristics for identifying papillary thyroid carcinoma from thyroid adenoma.
Xu D; Lai Y; Liu H; Li H; Feng N; Liu Y; Gong C; Zhang Y; Zhou J; Shen Y
Transl Res; 2024 Feb; 264():76-84. PubMed ID: 37863284
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules.
Yu S; Liu X; Zhang Y; Li J; Chen S; Zheng H; Reng R; Zhang C; Chen J; Chen L
Oncotarget; 2016 Dec; 7(51):84165-84177. PubMed ID: 27705935
[TBL] [Abstract][Full Text] [Related]
18. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
Zhao M; Yang F; Sang C; Yan C; Wang Z
J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
[TBL] [Abstract][Full Text] [Related]
19. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
[TBL] [Abstract][Full Text] [Related]
20. Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?
Razavi SA; Modarressi MH; Yaghmaei P; Tavangar SM; Hedayati M
Endocrine; 2017 Sep; 57(3):428-435. PubMed ID: 28755140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
